Acesso livre
Acesso livre

Emergências e UTI Pediátrica

M-A | Técnicas e tecnologias para melhorar os desfechos de cateter intravenoso periférico em pacientes pediátricos.

22 Nov, 2021 | 09:15h

Techniques and Technologies to Improve Peripheral Intravenous Catheter Outcomes in Pediatric Patients: Systematic Review and Meta-Analysis – Journal of Hospital Medicine (gratuito por tempo limitado)

Atualização sobre a síndrome inflamatória multissistêmica em crianças relacionada ao SARS-CoV-2.

11 Nov, 2021 | 16:17h

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2 – The Pediatric Infectious Diseases Journal

Conteúdos relacionados:

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Dez coisas a saber sobre a síndrome inflamatória multissistêmica em crianças (multisystem inflammatory syndrome in children – MIS-C).

4 Nov, 2021 | 12:01h

Ten Things to Know About MIS-C – American College of Cardiology

Conteúdos relacionados:

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Estudo randomizado | Entre crianças com pneumonia adquirida na comunidade que receberam alta hospitalar ou do departamento de emergência dentro de 48 horas, uma dose menor de amoxicilina oral foi não inferior a uma dose maior, e o tratamento por 3 dias foi não inferior ao curso de 7 dias.

3 Nov, 2021 | 11:05h

Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

Conteúdos relacionados:

ACP Guidance: Appropriate Use of Short-Course Antibiotics in Common Infections

RCT: 7 days of antibiotic therapy as good as 14 days for afebrile men with urinary tract infection.

RCT: A Seven-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales was noninferior to a 14-days course.

RCT: Among patients with prosthetic joint infection, antibiotic therapy for 6 weeks was NOT shown to be noninferior to antibiotic therapy for 12 weeks and resulted in a higher percentage of patients with unfavorable outcomes.

Randomized Trial: Seven vs. Fourteen Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia

 

Comentário no Twitter

 

A procalcitonina tem utilidade clínica no tratamento da pneumonia pediátrica adquirida na comunidade? Um debate de prós e contras.

28 Out, 2021 | 16:02h

Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate – JAC-Antimicrobial Resistance

PRO: Procalcitonin has clinical utility in children with community-acquired pneumonia

CON: Procalcitonin does not have clinical utility in children with community-acquired pneumonia

Estudo de coorte retrospectiva | Corticoterapia está relacionada a menor necessidade de drenagem cirúrgica em pacientes pediátricos com abscessos retro e parafaríngeos.

28 Out, 2021 | 15:58h

Corticosteroids in the Treatment of Pediatric Retropharyngeal and Parapharyngeal Abscesses – Pediatrics

M-A | Fatores de risco para um prognóstico ruim em crianças e adolescentes com COVID-19.

22 Out, 2021 | 12:22h

Risk factors for poor prognosis in children and adolescents with COVID-19: A systematic review and meta-analysis – EClinicalMedicine

Choosing Wisely na medicina pediátrica hospitalar | 5 novas recomendações para melhorar o valor.

20 Out, 2021 | 11:48h

Choosing Wisely in Pediatric Hospital Medicine: 5 New Recommendations to Improve Value – Hospital Pediatrics

Ver listas completas de práticas de baixo valor: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia E Choosing Wisely Canada

Estudo de coorte | Diagnósticos após hospitalização para um breve evento inexplicado resolvido.

8 Out, 2021 | 12:07h

Explanatory Diagnoses Following Hospitalization for a Brief Resolved Unexplained Event – Pediatrics

Efeitos neurológicos da COVID-19 em crianças.

1 Out, 2021 | 22:05h

Neurological Effects of COVID-19 in Children – Pediatric Clinics of North America

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.